DRIO
DarioHealth Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$7.17
+2.72%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
Market Cap
$70.26M
MomentumView details →
1D Return
+2.72%
YTD Return
−39.37%
RSI (14)
45.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
Market Cap
$70.26M
RSI (14)
45.6
MomentumView details →
1D Return
+2.72%
YTD Return
−39.37%
SummaryUpdated Jun 1, 2026
DarioHealth Corp. (NASDAQ:DRIO) is a digital therapeutics company that has undergone significant transformation since its founding. Originally incorporated in 2011 as LabStyle Innovations Corp., the company changed its name to DarioHealth Corp. in July 2016 and went public the same year. Based in New York, DarioHealth has evolved from a direct-to-consumer diabetes management company into a comprehensive digital health platform serving multiple chronic conditions through business-to-business partnerships with employers, health plans, and pharmaceutical companies across the United States, Canada, European Union, Australia, and New Zealand.
Similar companies
Latest newsMore news →
DarioHealth Corp. appointed Steven Nelson as Independent Consultant, effective October 1, 2026, with a grant of 30,000 shares of restricted common stock vesting on the first anniversary or upon a Change in Control.15d agoDarioHealth Corp. terminated Steven Nelson as President and Chief Commercial Officer, effective September 1, 2026, with severance including accrued wages, health insurance through September 30, 2026, and up to three months of COBRA reimbursement.15d agoDarioHealth reported second quarter 2026 financial results with revenue of $5.2 million, gross margin of 62%, and a 30% year-over-year decrease in operating loss.24d ago